Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial

The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app